Drug Sponsors

Pfizer to acquire NextWave Pharmaceuticals

Monday, October 22, 2012 12:56 PM

Pfizer, a global research-based pharmaceutical company, has agreed to acquire NextWave Pharmaceuticals, a privately-held, specialty pharmaceutical company focused on attention deficit/hyperactivity disorder (ADHD) and related central nervous system (CNS) disorders.

More... »

AMRI, Shire ink 5-year extension of API supply agreement

Monday, October 22, 2012 12:22 PM

AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.

More... »

Alnylam, Genzyme to develop and commercialize RNAi therapeutics in Asia

Monday, October 22, 2012 12:01 PM

Alnylam Pharmaceuticals, a biopharmaceutical company based in Cambridge, Mass., and Genzyme, a Sanofi company, have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

More... »

Charles River Labs, AstraZeneca enter strategic partnership

Monday, October 22, 2012 10:43 AM

AstraZeneca, a global biopharmaceutical company, has selected Charles River Laboratories International, a global provider of research products and services, as its preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

More... »

Neurovance closes $7M series A1 round for ADHD drug

Friday, October 19, 2012 12:09 PM

Neurovance, has closed a $7 million series A1 round led by existing investor Novartis Venture Fund to further advance development of EB-1020 for adult attention deficit hyperactivity disorder (ADHD).

More... »

BioCryst Pharmaceuticals to merge with Presidio Pharmaceuticals

Friday, October 19, 2012 11:34 AM

BioCryst Pharmaceuticals, a Durham, N.C.-based and developer of novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, and Presidio Pharmaceuticals, a San Francisco-based clinical stage specialty pharmaceutical company, have signed a definitive merger agreement for Presidio to be acquired by BioCryst in an all-stock transaction.

More... »

Merck Serono, Auxogyn collaborate on Eeva Test

Friday, October 19, 2012 11:01 AM

Merck Serono, the biopharmaceutical division of Merck, and Auxogyn, a company focused on translating scientific discoveries in early embryo development into clinical tools, have entered into a strategic agreement focused on Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test.

More... »

Clinical research sites honor Eli Lilly, Medpace with Eagle Awards

Monday, October 15, 2012 11:57 AM

The 2012 Eagle Awards, presented to the top sponsor and top CRO as voted by clinical research sites, honored Eli Lilly and Medpace on Saturday, Oct. 13, at the annual Site Solutions Summit.

More... »

Oramed, Medpace to collaborate on phase II trial

Monday, October 15, 2012 11:54 AM

Oramed, a subsidiary of Jerusalem-based Oramed Pharmaceuticals, a developer of oral drug delivery systems, has retained Medpace as CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »

Pharmaron forms strategic partnership with AstraZeneca

Monday, October 15, 2012 11:47 AM

Pharmaron, an R&D service provider for the pharmaceutical and biotech industries, is partnering with AstraZeneca to support its global innovative medicines units.

More... »